IXICO PLC

IXI
Delayed Quote. Delayed  - 01/20 11:35:08 am
89.5GBX --.--%
Business Summary
Healthcare
Pharmaceuticals & Medical Research
 Biotechnology & Medical Research
  Biotechnology & Medical Research
   Biotechnology & Medical Research - NEC
IXICO plc is a brain health company. The Company's brain health focus includes Alzheimer's disease, Huntington's disease, Parkinson's disease, behavioral health and adolescent mental health. It is a provider of clinical trials services to pharmaceutical companies. Its products include Assessa, mehealth, MyBrainBook and TrialTracker. Assessa is a decision-support tool for healthcare professionals looking to diagnose dementia and detect the underlying causes. mehealth is an online software for clinicians at the point-of-care to support decision making and improve the monitoring and treatment of patients. MyBrainBook is a digital platform to improve the quality of life and service delivery for people living with dementia and their supporters. TrialTracker is a Web-based system that allows users to track their imaging-based research study or clinical trial in real time. It is also collaborating with partners to develop companion digital health products.
Sales per Business
20192020
GBP
(in Million)
%GBP
(in Million)
%
Clinical Trials Services 7.56100% 9.53100%
Sales per region
2020
GBP
(in Million)
%
United Kingdom 6.3766.9%
United States 1.9920.9%
Europe 1.1712.3%
Managers
Name Title
Giulio Cerroni Chief Executive Officer & Executive Director
Charles Alexander Evan Spicer Non-Executive Chairman
Grant Robert Nash CFO, Secretary & Executive Director
Michelle Lax Vice President-Clinical Operations
John Bradshaw Independent Non-Executive Director
Mark Robert Warne Senior Independent Non-Executive Director
John Hall Senior Vice President-Commercial Operations
Lammert Albers Chief Business Officer
Shareholders
Name Equities %
BGF Investment Management Ltd. 8,924,000 19.0%
Octopus Investments Ltd. 6,408,400 13.6%
Gresham House Asset Management Ltd. 5,357,100 11.4%
Amati Global Investors Ltd. 5,031,300 10.7%
Amati Global Investors Ltd. (Venture Capital) 5,030,882 10.7%
Canaccord Genuity Wealth Ltd. 4,683,071 9.94%
Hargreave Hale Ltd. 3,651,288 7.75%
Livingbridge EP LLP 2,411,000 5.12%
Hargreaves Lansdown Stockbrokers Ltd. 1,934,000 4.11%
Brett Gordon 1,381,797 2.93%
Company contact information
IXICO Plc
Griffin Court
15 Long Lane
4th Floor
London, Greater London EC1A 9PN

Phone : +44.20.3763.7499
Web : http://www.ixico.com
Sector Biotechnology & Medical Research - NEC
1st jan.Capi. (M$)
IXICO PLC-12.68%57
MODERNA, INC.19.66%49 468
LONZA GROUP AG1.97%48 472
CELLTRION, INC.-13.37%38 667
IQVIA HOLDINGS INC.5.47%36 230
SEAGEN INC.7.75%34 149
HANGZHOU TIGERMED CONSULTING CO.,LTD7.64%21 275
INCYTE CORPORATION4.12%20 577
ALNYLAM PHARMACEUTICALS, INC.29.58%19 566
PHARMARON BEIJING CO., LTD.16.82%15 255
CRISPR THERAPEUTICS AG29.51%14 657
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.9.55%13 873
BIO-TECHNE CORPORATION10.78%13 582
PPD, INC.5.04%12 568
QIAGEN N.V.2.48%12 316
ICON PUBLIC LIMITED COMPANY10.33%11 353
IONIS PHARMACEUTICALS, INC.7.94%8 533
PRA HEALTH SCIENCES, INC.5.97%8 527
ACADIA PHARMACEUTICALS INC.-0.17%8 485
SYNEOS HEALTH, INC.13.21%8 015
UNITED THERAPEUTICS CORPORATION13.06%7 626